MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development

Yavorski,John  M.; Blanck,George

doi:10.3892/mco.2017.1432

MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development

Authors:
- John M. Yavorski
- George Blanck
View Affiliations

Affiliations: Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
Published online on: September 29, 2017 https://doi.org/10.3892/mco.2017.1432
Pages: 1119-1121

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of tumor cell expression of major histocompatibility class II (MHCII) has been controversial, with evidence indicating that tumor cell expression of MHCII may lead to an anti‑tumor immune response and to tumor cell apoptosis and that MHCII has pro‑tumorigenic functions. The cancer genome atlas (TCGA) indicates numerous deleterious mutations for the highly specific, MHCII transcriptional activation proteins, RFX5, RFXAP, RFXANK and CIITA. Also, mutations in the non‑polymorphic, human leukocyte antigen (HLA)‑DRA gene, which encodes the heavy chain for the most prominent human MHCII molecule, HLA‑DR, are common. For many, if not most TCGA cancer datasets, the MHCII specific mutations do not associate with clinical outcomes. However, stomach carcinoma represents an exception, where the data indicate that MHCII‑specific mutations are associated with a more favorable outcome. These data raise the question of whether stomach cancer mutations represent effective haploinsufficiency or whether mutations that are associated with a favorable outcome occur with other stomach cancer molecular features that limit the function of the two alleles that represent these MHCII‑related proteins.

View Figures

View References

1	Lu Y, Boss JM, Hu SX, Xu HJ and Blanck G: Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction. J Immunol. 156:2495–2502. 1996.PubMed/NCBI
2	Blanck G: Components of the IFN-gamma signaling pathway in tumorigenesis. Arch Immunol Ther Exp (Warsz). 50:151–158. 2002.PubMed/NCBI
3	Xi H, Eason DD, Ghosh D, Dovhey S, Wright KL and Blanck G: Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene. 18:5889–5903. 1999. View Article : Google Scholar : PubMed/NCBI
4	Lu Y, Ussery GD, Muncaster MM, Gallie BL and Blanck G: Evidence for retinoblastoma protein (RB) dependent and independent IFN-gamma responses: RB coordinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells. Oncogene. 9:1015–1019. 1994.PubMed/NCBI
5	Lu Y, Tschickardt ME, Schmidt BJ and Blanck G: IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: Relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. Immunol Cell Biol. 75:325–332. 1997. View Article : Google Scholar : PubMed/NCBI
6	Xi H, Goodwin B, Shepherd AT and Blanck G: Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. Oncogene. 20:4219–4227. 2001. View Article : Google Scholar : PubMed/NCBI
7	Xi H and Blanck G: Interferon regulatory factor-2 point mutations in human pancreatic tumors. Int J Cancer. 87:803–808. 2000. View Article : Google Scholar : PubMed/NCBI
8	Eason DD, Coppola D, Livingston S, Shepherd AT and Blanck G: Loss of MHC class II inducibility in hyperplastic tissue in Rb-defective mice. Cancer Lett. 171:209–214. 2001. View Article : Google Scholar : PubMed/NCBI
9	Zhu X, Pattenden S and Bremner R: pRB is required for interferon-gamma-induction of the MHC class II abeta gene. Oncogene. 18:4940–4947. 1999. View Article : Google Scholar : PubMed/NCBI
10	Osborne A, Zhang H, Yang WM, Seto E and Blanck G: Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol Cell Biol. 21:6495–6506. 2001. View Article : Google Scholar : PubMed/NCBI
11	Osborne AR, Zhang H, Fejer G, Palubin KM, Niesen MI and Blanck G: Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: An Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. J Biol Chem. 279:28911–28919. 2004. View Article : Google Scholar : PubMed/NCBI
12	Chornoguz O, Gapeev A, O'Neill MC and Ostrand-Rosenberg S: Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients. Mol Cell Proteomics. 11:1457–1467. 2012. View Article : Google Scholar : PubMed/NCBI
13	Srivastava MK, Bosch JJ, Wilson AL, Edelman MJ and Ostrand-Rosenberg S: MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells. Int J Cancer. 127:2612–2621. 2010. View Article : Google Scholar : PubMed/NCBI
14	Truman JP, Choqueux C, Charron D and Mooney N: HLA class II molecule signal transduction leads to either apoptosis or activation via two different pathways. Cell Immunol. 172:149–157. 1996. View Article : Google Scholar : PubMed/NCBI
15	Le E, Zhang H and Blanck G: CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells. Anticancer Res. 25:3889–3892. 2005.PubMed/NCBI
16	Stoll RJ, Thompson GR, Samy MD and Blanck G: De novo, systemic, deleterious amino acid substitutions are common in large cytoskeleton-related protein coding regions. Biomed Rep. 6:211–216. 2017. View Article : Google Scholar : PubMed/NCBI
17	Choi Y, Sims GE, Murphy S, Miller JR and Chan AP: Predicting the functional effect of amino acid substitutions and indels. PLoS One. 7:e466882012. View Article : Google Scholar : PubMed/NCBI
18	Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE and Abraham I: Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: A systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med. 5:1481–1491. 2016. View Article : Google Scholar : PubMed/NCBI
19	Khawar MB, Abbasi MH and Sheikh N: IL-32: A novel pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis. Mediators Inflamm. 2016:84137682016. View Article : Google Scholar : PubMed/NCBI
20	Fornaro R, Caratto M, Caratto E, Caristo G, Fornaro F, Giovinazzo D, Sticchi C, Casaccia M and Andorno E: Colorectal cancer in patients with inflammatory bowel disease: The need for a real surveillance program. Clin Colorectal Cancer. 15:204–212. 2016. View Article : Google Scholar : PubMed/NCBI
21	Macián F, Im SH, García-Cózar FJ and Rao A: T-cell anergy. Curr Opin Immunol. 16:209–216. 2004. View Article : Google Scholar : PubMed/NCBI
22	Kohlmeier JE, Chan MA and Benedict SH: Costimulation of naive human CD4 T cells through intercellular adhesion molecule-1 promotes differentiation to a memory phenotype that is not strictly the result of multiple rounds of cell division. Immunology. 118:549–558. 2006.PubMed/NCBI
23	Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, Iessi E, Gentile M, Luciani F, Parmiani G, Rivoltini L, et al: Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res. 66:3629–3638. 2006. View Article : Google Scholar : PubMed/NCBI
24	Lloyd MC, Szekeres K, Brown JS and Blanck G: Class II transactivator expression in melanoma cells facilitates T-cell engulfment. Anticancer Res. 35:25–29. 2015.PubMed/NCBI